We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 418.30
Bid: 420.00
Ask: 420.40
Change: -6.70 (-1.58%)
Spread: 0.40 (0.095%)
Open: 425.90
High: 426.40
Low: 417.90
Prev. Close: 425.00
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

19 Oct 2016 07:00

RNS Number : 8825M
Rentokil Initial PLC
19 October 2016
 

RENTOKIL INITIAL PLC (RTO)

THIRD QUARTER TRADING UPDATE

19 October 2016

 

 

 (£m)

Q3 2016

Growth

AER

AER

CER

Revenue

578.3

32.1%

15.7%

Revenue - ongoing operations1

576.7

33.1%

16.6%

 

 

Performance Overview (CER)

Revenue from ongoing operations increased by 16.6% in Q3, of which 3.1% was organic (H1 2016: 2.5%) and 13.5% was from acquisitions. Year to date we have delivered organic growth of 2.7%. Pest Control delivered an excellent performance in the quarter, growing organically by 5.9%, and our Hygiene business demonstrated further improvement, growing organically by 3.2%. Growth in our Emerging (+20.4%) and Growth (+26.3%) markets was once again particularly strong. Our operations within the Manage for Value quadrant grew by 2.3% while the rate of revenue decline in our Protect and Enhance markets was largely unchanged from Q1 and Q2 at 1%.

The majority of our regions have performed well in the period reflecting good performances in Asia, Pacific, Latin America, the UK and in our largest market, North America. While conditions remain tough in parts of Europe, particularly in France, overall the region delivered modest revenue growth in Q3.

Also in the quarter Rentokil was proud to provide in partnership with the Rio de Janeiro health authorities, Pest Control, including innovative mosquito elimination, in advance of and during the very successful Rio 2016 Olympic and Paralympic Games.

M&AThe Company acquired 13 businesses in the quarter including ten in Pest Control and two in Hygiene, as well as the acquisition of Residex, a Pest Control and Turf Products Distribution business, as announced on 7 July. All of the acquisitions were in Emerging or Growth markets. Combined annual revenues of the businesses acquired totalled £88m in the 12 months immediately prior to acquisition. For the nine months to 30 September we have acquired 33 businesses with combined annual revenues of £109m. The integrations of Steritech and Residex are both progressing well.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am pleased with our performance in the third quarter. Pest Control grew organically by almost 6%, reflecting good performances in Asia, Pacific, Latin America, the UK and our key growth market of North America. I am also encouraged by ongoing traction in our Hygiene business which delivered organic growth of 3.2%. Our guidance for the full year is unchanged."

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

John Sunnucks

Bell Pottinger

0203 772 2549

 

 

 

AER - actual exchange rates; CER - constant 2015 exchange rates

 

1ongoing revenue excludes the financial performance of disposed and closed businesses but includes results from acquisitions

 

This announcement contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
QRTFMMMGVRFGVZM
Date   Source Headline
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes
10th Nov 20232:28 pmRNSDirector/PDMR Shareholding
3rd Nov 20234:26 pmRNSHolding(s) in Company
3rd Nov 20234:22 pmRNSDirector/PDMR Shareholding
1st Nov 202312:50 pmRNSHolding(s) in Company
31st Oct 202311:45 amRNSHolding(s) in Company
30th Oct 20233:03 pmRNSDirector/PDMR Shareholding
30th Oct 202311:55 amRNSCredit rating update
19th Oct 20237:00 amRNSQ3 Trading Update
2nd Oct 202311:35 amRNSBlock listing Interim Review
27th Sep 20232:35 pmRNSDirector/PDMR Shareholding
1st Aug 202312:42 pmRNSDirector/PDMR Shareholding
27th Jul 20237:00 amRNS2023 Interim Results
29th Jun 20239:00 amRNSNotice of Management Presentation
23rd Jun 20235:58 pmRNSDirector/PDMR Shareholding
19th May 20233:03 pmRNSDirector/PDMR Shareholding
12th May 20239:09 amRNSDirector/PDMR Shareholding
11th May 20239:17 amRNSResult of AGM
28th Apr 202310:55 amRNSHolding(s) in Company
21st Apr 20232:41 pmRNSDirector/PDMR Shareholding
20th Apr 20237:00 amRNSQ1 Trading Update
4th Apr 20239:37 amRNSAnnual Financial Report
3rd Apr 202310:08 amRNSBlock listing Interim Review
23rd Mar 20239:42 amRNSDirector/PDMR Shareholding
20th Mar 20234:47 pmRNSDirector/PDMR Shareholding
16th Mar 20237:05 amRNSDirectorate Change
16th Mar 20237:00 amRNSFinal Results
9th Mar 20239:23 amRNSDirector Declaration
27th Feb 20238:55 amRNSNotice of Management Presentation
9th Nov 20224:33 pmRNSDirector Declaration
1st Nov 20222:25 pmRNSCorrection: Q3 Trading Update
1st Nov 20227:00 amRNSQ3 Trading Update
31st Oct 20224:03 pmRNSTotal Voting Rights
24th Oct 20225:15 pmRNSHolding(s) in Company
21st Oct 20224:42 pmRNSHolding(s) in Company
20th Oct 202212:35 pmRNSHolding(s) in Company
19th Oct 202211:43 amRNSHolding(s) in Company
18th Oct 20225:22 pmRNSHolding(s) in Company
17th Oct 20226:07 pmRNSHolding(s) in Company
17th Oct 202211:51 amRNSHolding(s) in Company
14th Oct 20224:39 pmRNSHolding(s) in Company
14th Oct 20224:37 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.